Improving the Biomarker Pipeline to Develop and Evaluate Cancer Screening Tests

被引：32

作者：

Baker, Stuart G. ^{[1
]}

机构：

[1] NCI, Biometry Res Grp, Canc Prevent Div, Bethesda, MD 20892 USA

来源：

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2009年 / 101卷 / 16期

关键词：

CUMULATIVE RISK; CLINICAL-TRIALS; MARKERS; DESIGN; CLASSIFICATION; MICROARRAYS; STANDARDS;

D O I：

10.1093/jnci/djp186

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The biomarker pipeline to develop and evaluate cancer screening tests has three stages: identification of promising biomarkers for the early detection of cancer, initial evaluation of biomarkers for cancer screening, and definitive evaluation of biomarkers for cancer screening. Statistical and biological issues to improve this pipeline are discussed. Although various recommendations, such as identifying cases based on clinical symptoms, keeping biomarker tests simple, and adjusting for postscreening noise, have been made previously, they are not widely known. New recommendations include more frequent specimen collection to help identify promising biomarkers and the use of the paired availability design with interval cases (symptomatic cancers detected in the interval after screening) for initial evaluation of biomarkers for cancer screening.

引用

页码：1116 / 1119

页数：4

共 34 条

[31] Opinion - Bias as a threat to the validity of cancer molecular-marker research [J].

Ransohoff, DF .

NATURE REVIEWS CANCER, 2005, 5 (02) :142-149

[32] Theories of carcinogenesis: An emerging perspective [J].

Sonnenschein, Carlos ;

Soto, Ana M. .

SEMINARS IN CANCER BIOLOGY, 2008, 18 (05) :372-377

[33] CLINICAL-PREDICTION RULES - APPLICATIONS AND METHODOLOGICAL STANDARDS [J].

WASSON, JH ;

SOX, HC ;

NEFF, RK ;

GOLDMAN, L .

NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (13) :793-799

[34] Estimating the cumulative risk of a false-positive test in a repeated screening program [J].

Xu, JL ;

Fagerstrom, RM ;

Prorok, PC ;

Kramer, BS .

BIOMETRICS, 2004, 60 (03) :651-660

← 1 2 3 4 →